Shuttle Pharmaceuticals Holdings (SHPH) Return on Capital Employed (2022 - 2026)
Shuttle Pharmaceuticals Holdings (SHPH) posted quarterly Return on Capital Employed of 394.16% for Q1 2026, up 4151.0% year-over-year from 9.27% in Q1 2025, and down 131.67% quarter-over-quarter from 1244.66% in Q4 2025.
Shuttle Pharmaceuticals Holdings (SHPH) Return on Capital Employed (2022 - 2026) Analysis & Trends
Shuttle Pharmaceuticals Holdings' Return on Capital Employed history runs 5 years deep, the most recent figure standing at 394.16% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 4151.0% year-over-year to 394.16%; the TTM figure through Mar 2026 stood at 394.16% (up 4151.0% YoY), while the FY2025 annual figure was 807.51%, up 109305.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 394.16%, down from 1244.66% in the prior quarter.
- The five-year high for Return on Capital Employed was 1244.66% in Q4 2025, with the low at 13704.01% in Q4 2024.
- The 5-year median for Return on Capital Employed is 194.02% (2024), against an average of 1662.76%.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed sank 1359919 bps in 2024, then surged 1494866 bps in 2025.
- Shuttle Pharmaceuticals Holdings' Return on Capital Employed stood at 29.14% in 2022, then sank by 260 bps to 104.82% in 2023, then sank by 12974 bps to 13704.01% in 2024, then surged by 109 bps to 1244.66% in 2025, then plunged by 132 bps to 394.16% in 2026.
- Business Quant data shows SHPH's Return on Capital Employed at 394.16% in Q1 2026, 1244.66% in Q4 2025, and 426.21% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 6.60% |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 17.16% |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 6.07% |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 22.04% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -0.29% |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 18.67% |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 5.52% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Shuttle Pharmaceuticals Holdings | 1.86 Mn | 1.86 Mn | - | -394.16% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -394.16% |
| Dec 31, 2025 | 1,244.66% |
| Sep 30, 2025 | -426.21% |
| Jun 30, 2025 | -314.72% |
| Mar 31, 2025 | -435.67% |
| Dec 31, 2024 | -13,704.01% |
| Sep 30, 2024 | -8,568.55% |
| Jun 30, 2024 | -239.68% |
| Mar 31, 2024 | -148.37% |
| Dec 31, 2023 | -104.82% |
| Sep 30, 2023 | -70.45% |
| Jun 30, 2023 | -47.71% |
| Mar 31, 2023 | -39.85% |
| Dec 31, 2022 | -29.14% |